Flying raptor! —
SpaceX has shipped its Mars engine to Texas for tests.
If a full-scale Raptor engine is undergoing tests, the company is progressing to Mars.
Read more
Gone are the days for US Tech on quick and easy money — China is making the US Tech face the realities of being relevant or being replaced. My suggestion for folks like Apple, Microsoft, FB take a chapter from Alphabet’s playbook and focus on those technologies that truly revolutionize the technology landscape, multiple industries, etc. Stop throwing money at gadgets and easy replicated apps and services. Let China own it because eventually they will. Focus on things like biocomputing, QC, space, etc. Because anything copied multiple times and quickly means it is easily replaced by the next cheaper and better gadget.
The recent Uber acquisition drama in China has given a new twist to the country’s technology sector.
Domestic tech companies are straining at the leash to go global while also defending their home markets from foreign competitors.
Even before the Didi/Uber battle unfolded, China’s tech firms were making waves. The global industry has been anxiously watching to see if the Chinese behemoths play a big part in the mergers and acquisitions game as they look to gulp down foreign companies. Home-grown giants such as Alibaba, and Tencent with its WeChat platform, have expanded across several countries although they still have a long road to travel before making worldwide impact.
Finally a trailer for this!
And it looks like it’s been worth the wait!
The first trailer from Arrival, Denis Villeneuve’s adaptation of the Ted Chiang short story Story Of Your Life is finally here. It looks like an Oscar contender wrapped in a high-concept blockbuster package, which is a way to say it looks great.
And honestly, even if this isn’t an Alien Structure of some kind, it won’t be long before we DO spot some form of alien mega-structure somewhere in this galaxy of ours. I wouldn’t be surprised to find out that we ALREADY have, but mistook it for a natural structure of some kind.
The leading natural explanation for the ‘alien megastructure’ star has been discredited, leaving ET as a viable possibility.
Read more
Bebionic Photo
Posted in cyborgs, transhumanism
Prospector-1™
Posted in robotics/AI, space travel
1™, the world’s first commercial interplanetary mining mission, will fly to and rendezvous with a near-Earth asteroid to determine its value as a source of space resources. The destination asteroid will be chosen from a group of top candidates selected by the world renowned team of asteroid experts at Deep Space Industries.
Once the spacecraft arrives at the asteroid, the autonomous spacecraft will map the surface and subsurface, taking visual and infrared imagery and mapping overall water content. With the initial science campaign complete, Prospector-1 will use its water thrusters to gently touch down on the asteroid, measuring the target’s geophysical characteristics.
Prospector-1 is a small spacecraft that strikes the ideal balance between cost and performance. In addition to radiation-tolerant payloads and avionics, all DSI spacecraft notably use the Comet line of water propulsion systems, which expel superheated water vapor to generate thrust. Water will be the first asteroid mining product, so using water as propellant will provide future DSI spacecraft with the ability to refuel in space.
Read more
“Waves of virtual reality and augmented reality startups have their funding. Venture capitalists invested $1.7 billion in the AR/VR sector in the 12 months ended March 2016, and $1.2 billion of that was invested in the first quarter of this year alone, according to Digi-Capital.”
“These days every company is a tech company, but some have better niches, faster growth, more attractive offerings or more favorable share prices than others.”
With only 9 days left on the SENS cancer fundraiser here is an article from Fightaging! that explains why finding novel solutions to treating cancer is critical in the roadmap to longer healthier lives.
This year’s SENS rejuvenation research crowdfunding event puts the spotlight on the SENS Research Foundation’s cancer program. So far more than 300 people have donated, and more than $26,000 has been raised; with ten days left to go, it won’t take that much more of an effort to reach the same number of donors and the same level of support given to last year’s fundraiser, and which led to the success in that research program. As for all of the SENS research initiatives in the science of aging, the SENS Research Foundation’s work on cancer aims to support a big, bold goal in medicine: to build a single type of therapy that can be used to effectively treat all forms of cancer. When achieved, that will greatly increase the pace of progress towards control of cancer, the goal of finally ending cancer as a threat to health. At present the cancer research community spends much of its time and funding on approaches that are highly specific to only one or only a few of the hundred of subtypes of cancer. That is no way to win any time soon, as even with the vast funding devoted to cancer research, there are just too many forms of cancer and too few researchers. What is needed is to change the strategy, to focus on approaches to the treatment of cancer that are no more expensive to develop, but that far more patients can benefit from.
The most promising approach to a universal cancer therapy is to block telomere lengthening in cancerous tissues. Telomeres are a part of the mechanism that limits cell division in all human cells other than stem cells, repeating DNA sequences at the ends of chromosomes that shorten every time a cell divides. In order to achieve unfettered growth all cancers must bypass this limit by continually lengthening their telomeres, a goal that is achieved through mutations that allow cancer cells to use telomerase or the alternative lengthening of telomeres (ALT) processes. If both telomerase and ALT can be blocked in cancer tissue, then the cancer will wither; this is such a fundamental piece of cellular machinery that there is no expectation that cancer cells could find a way around it. Block only one of these two methods of telomere lengthening, however, and the cancer will probably switch to use the other. This has been observed in mice.
Thus it is very important that the research community deploy both telomerase and ALT blockades as a part of a prospective universal cancer therapy. Unfortunately while a number of groups are working on telomerase interdiction, and telomerase is very well studied these days, ALT is still poorly characterized, at the frontiers of what is known of cell biology. ALT doesn’t occur in normal cells, and thus despite the fact that 10% of cancers make use of it, only recently have the necessary tools been developed to work towards understanding and intervention. The SENS Research Foundation is picking up the slack in this overlooked area of development, and with our support is working towards ensuring that the first universal cancer therapies can in fact target both telomerase and ALT, and therefore succeed.